1. NF-κB
  2. NF-κB

(-)-DHMEQ (Synonyms: Dehydroxymethylepoxyquinomicin)

Cat. No.: HY-14645 Purity: 98.05% ee.: 100.00%
Data Sheet SDS Handling Instructions

(-)-DHMEQ, the eutomer of DHMEQ , is a newly developed NF-kB inhibitor, inhibits nuclear factor kB activation with IC50 value of 20 ug/mL, the activity is stronger than (+)-DHMEQ (HY-14645A).

For research use only. We do not sell to patients.
(-)-DHMEQ Chemical Structure

(-)-DHMEQ Chemical Structure

CAS No. : 287194-40-5

Size Price Stock Quantity
10 mM * 1 mL in DMSO $201 In-stock
2 mg $140 In-stock
5 mg $220 In-stock
10 mg $300 In-stock
25 mg $600 In-stock
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

Customer Review

Other Forms of (-)-DHMEQ:

    (-)-DHMEQ purchased from MCE. Usage Cited in: Biol Pharm Bull. 2017;40(10):1669-1677.

    A549 transfectants stably expressing RelB WT (A) are preincubated with various concentrations of (–)-DHMEQ for 1 h and then incubated with or without LTβ (25 ng/mL) for 2 h in the presence or absence of (−)-DHMEQ.

    (-)-DHMEQ purchased from MCE. Usage Cited in: Biol Pharm Bull. 2017;40(10):1669-1677.

    A549 transfectants stably expressing RelB (C144S) (B) are preincubated with various concentrations of (–)-DHMEQ for 1 h and then incubated with or without LTβ (25 ng/mL) for 2 h in the presence or absence of (−)-DHMEQ.
    • Biological Activity

    • Protocol

    • Technical Information

    • Purity & Documentation

    • References

    Description

    (-)-DHMEQ, the eutomer of DHMEQ , is a newly developed NF-kB inhibitor, inhibits nuclear factor kB activation with IC50 value of 20 ug/mL, the activity is stronger than (+)-DHMEQ (HY-14645A). target: NF-kB [1] IC 50: 20 ug/mL [2] In vitro: (-)-DHMEQ significantly reduces eosinophilicairway inflammation and levels of Th2 cytokines in bronchoalveolar lavage fluid in theacute model. It also inhibits parameters of airway remodelling including mucus produc-tion, peribronchial fibrosis and the expression of a-smooth muscle actin.[1] (-)-DHMEQ strongly inhibits cyclin D1 and vascular en-dothelial growth factor (VEGF) promoter activity and decreased the levels of cyclin D1 protein and VEGF mRNA in KB cells。 (-)-DHMEQ strongly inhibits cyclin D1 and vascular en-dothelial growth factor (VEGF) promoter activity and decreasedthe levels of cyclin D1 protein and VEGF mRNA in KB cells.[2] (-)-DHMEQ suppresses the tumour growth and anti-inflammatory effects.[3] (-)-DHMEQ inhibits TPA-induced activation of NF-kB and differentiation of THP-1 cells into macrophages.[5] In vivo: When (-)-DHMEQ is injects into mice 2 h before LPS injection, the survival of the LPS-injected mice was prolonged. When (-)-DHMEQ is injected twice (2 h before LPS injection and the day after LPS injection), all the mice are rescued. (-)-DHMEQ can be utilized for the prevention and treatment of endotoxin shock.[3]

    References
    Molecular Weight

    261.23

    Formula

    C₁₃H₁₁NO₅

    CAS No.

    287194-40-5

    Storage
    Powder -20°C 3 years
      4°C 2 years
    In solvent -80°C 6 months
      -20°C 1 month
    Shipping

    Room temperature in continental US; may vary elsewhere

    Solvent & Solubility

    DMSO: ≥ 32 mg/mL

    * "<1 mg/mL" means slightly soluble or insoluble. "≥" means soluble, but saturation unknown.

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product name

     

    Salutation

    Applicant name *

     

    Email address *

    Phone number

     

    Organization name *

    Country *

     

    Requested quantity *

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    (-)-DHMEQ
    Cat. No.:
    HY-14645
    Quantity: